Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
ANIK - Anika Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.00
DETAILS
HIGH:
$21.00
LOW:
$21.00
MEDIAN:
$21.00
CONSENSUS:
$21.00
UPSIDE:
9.95%
Stock News
Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast
Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings. Valuation and Earnings This table compares Anika Therapeutics
Corient Private Wealth LP Takes Position in Anika Therapeutics Inc. $ANIK
Corient Private Wealth LP bought a new stake in shares of Anika Therapeutics Inc. (NASDAQ: ANIK) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 34,059 shares of the biotechnology company's stock, valued at approximately $498,000. Corient Private Wealth LP owned 0.25% of Anika Therapeutics as
Hsbc Holdings PLC Invests $727,000 in Anika Therapeutics Inc. $ANIK
Hsbc Holdings PLC purchased a new position in shares of Anika Therapeutics Inc. (NASDAQ: ANIK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,105 shares of the biotechnology company's stock, valued at approximately $727,000. Hsbc Holdings PLC owned about 0.37% of
Best Momentum Stocks to Buy for August 26th
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Stocks With Recent Price Strength to Tap August Rally
Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Anika Therapeutics Q2 Earnings Call Highlights
Anika Therapeutics NASDAQ: ANIK reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability.
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2026 financial results before the opening of the market on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
Bullish On Anika Therapeutics's Pullback As Integrity Scales
Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK's Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks.
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Reports First Quarter 2026 Financial Results
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026.
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Is Anika Therapeutics Inc (ANIK) a Bargain After 3.1% Drop? GF Value Says Undervalued
On April 10, 2026, Anika Therapeutics Inc (ANIK) shares fell 3.1% to a current price of $14.76. This price is within a 52-week range of $7.87 to $15.48, indicat